VTV THERAPEUTICS INC- CL A (VTVT) Stock Price, Forecast & Analysis
NASDAQ:VTVT • US9183852048
VTVT Key Statistics, Chart & Performance
The current stock price of VTVT is 33.87 USD. In the past month the price decreased by -9.07%. In the past year, price increased by 56.05%.
VTVT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VTVT. When comparing the yearly performance of all stocks, VTVT is one of the better performing stocks in the market, outperforming 87.79% of all stocks.
VTVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VTVT. No worries on liquidiy or solvency for VTVT as it has an excellent financial health rating, but there are worries on the profitability.
VTVT Financial Highlights
Over the last trailing twelve months VTVT reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS increased by 24.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.59% | ||
| ROE | -33.27% | ||
| Debt/Equity | 0 |
VTVT Forecast & Estimates
11 analysts have analysed VTVT and the average price target is 52.22 USD. This implies a price increase of 54.19% is expected in the next year compared to the current price of 33.87.
For the next year, analysts expect an EPS growth of -13.59% and a revenue growth -100% for VTVT
VTVT Ownership
VTVT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VTVT
Company Profile
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Company Info
VTV THERAPEUTICS INC- CL A
3980 Premier Dr, Suite 310
High Point NORTH CAROLINA 27265 US
CEO: Stephen L. Holcombe
Employees: 23
Phone: 13368410300
VTV THERAPEUTICS INC- CL A / VTVT FAQ
What does VTVT do?
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
What is the current price of VTVT stock?
The current stock price of VTVT is 33.87 USD. The price decreased by -7.18% in the last trading session.
What is the dividend status of VTV THERAPEUTICS INC- CL A?
VTVT does not pay a dividend.
How is the ChartMill rating for VTV THERAPEUTICS INC- CL A?
VTVT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of VTV THERAPEUTICS INC- CL A (VTVT) based on its PE ratio?
VTV THERAPEUTICS INC- CL A (VTVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.32).
Can you provide the market cap for VTV THERAPEUTICS INC- CL A?
VTV THERAPEUTICS INC- CL A (VTVT) has a market capitalization of 133.45M USD. This makes VTVT a Micro Cap stock.
What is the Short Interest ratio of VTV THERAPEUTICS INC- CL A (VTVT) stock?
The outstanding short interest for VTV THERAPEUTICS INC- CL A (VTVT) is 1.03% of its float.